Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Sarepta Therapeutics (SRPT) PT Lowered to $91 at RBC Capital
March 1, 2017 6:35 AM ESTRBC Capital lowered its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $91.00 (from $98.00) while maintaining a Outperform rating amid conservative guidance.
Analyst Simos Simeonidis commented, "Sarepta provided sales guidance for EXONDYS 51 on tonight's call, which clearly disappointed investors (SRPT... More
Sarepta Therapeutics (SRPT) Misses Q4 EPS by 29c, Sales Beat
February 28, 2017 4:46 PM ESTSarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($1.62), $0.29 worse than the analyst estimate of ($1.33). Revenue for the quarter came in at $5.42 million versus the consensus estimate of $4.72 million.
2016 was a transformative year, with the FDA accelerated approval of EXONDYS 51. In 2017, we are focused... More
